Advertisement

Relation of Elevated Heart Rate in Patients With Heart Failure With Reduced Ejection Fraction to One-Year Outcomes and Costs

Published:December 29, 2015DOI:https://doi.org/10.1016/j.amjcard.2015.12.031
      There are limited data describing outcomes associated with an elevated heart rate in patients with heart failure with reduced ejection fraction (HFrEF) in routine clinical practice. We identified patients with HFrEF at Duke University Hospital undergoing echocardiograms and heart rate assessments without paced rhythms or atrial fibrillation. Outcomes (all-cause mortality or hospitalization and medical costs per day alive) were assessed using electronic medical records, hospital cost accounting data, and national death records. Patients were stratified by heart rate (<70 and ≥70 beats/min) and compared using generalized linear models specified with gamma error distributions and log links for costs and proportional hazard models for mortality/hospitalization. Of 722 eligible patients, 582 patients (81%) were treated with β blockers. The median heart rate was 81 beats/min (25th and 75th percentiles 69 to 96) and 527 patients (73%) had a heart rate ≥70 beats/min. After multivariate adjustment, a heart rate ≥70 beats/min was associated with increased 1-year all-cause mortality or hospitalization, hazard ratio 1.37 (95% CI 1.07 to 1.75) and increased medical costs per day alive, cost ratio 2.03 (95% CI 1.53 to 2.69). In conclusion, at a large tertiary care center, despite broad use of β blockers, a heart rate ≥70 beats/min was observed in 73% of patients with HFrEF and associated with worse 1-year outcomes and increased direct medical costs per day alive.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Castagno D.
        • Skali H.
        • Takeuchi M.
        • Swedberg K.
        • Yusuf S.
        • Granger C.B.
        • Michelson E.L.
        • Pfeffer M.A.
        • McMurray J.J.
        • Solomon S.D.
        Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program.
        J Am Coll Cardiol. 2012; 59: 1785-1795
        • O'Connor C.M.
        • Abraham W.T.
        • Albert N.M.
        • Clare R.
        • Gattis Stough W.
        • Gheorghiade M.
        • Greenberg B.H.
        • Yancy C.W.
        • Young J.B.
        • Fonarow G.C.
        Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF).
        Am Heart J. 2008; 156: 662-673
        • Greene S.J.
        • Vaduganathan M.
        • Wilcox J.E.
        • Harinstein M.E.
        • Maggioni A.P.
        • Subacius H.
        • Zannad F.
        • Konstam M.A.
        • Chioncel O.
        • Yancy C.W.
        • Swedberg K.
        • Butler J.
        • Bonow R.O.
        • Gheorghiade M.
        The prognostic significance of heart rate in patients hospitalized for heart failure with reduced ejection fraction in sinus rhythm: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) trial.
        JACC Heart Fail. 2013; 1: 488-496
        • Habal M.V.
        • Liu P.P.
        • Austin P.C.
        • Ross H.J.
        • Newton G.E.
        • Wang X.
        • Tu J.V.
        • Lee D.S.
        Association of heart rate at hospital discharge with mortality and hospitalizations in patients with heart failure.
        Circ Heart Fail. 2014; 7: 12-20
        • Laskey W.K.
        • Alomari I.
        • Cox M.
        • Schulte P.J.
        • Zhao X.
        • Hernandez A.F.
        • Heidenreich P.A.
        • Eapen Z.J.
        • Yancy C.
        • Bhatt D.L.
        • Fonarow G.C.
        • the AHA Get With The Guidelines-Heart Failure Program
        Heart rate at hospital discharge in patients with heart failure is associated with mortality and rehospitalization.
        J Am Heart Assoc. 2015; 4 (pii: e001626)
        • Swedberg K.
        • Komajda M.
        • Böhm M.
        • Borer J.S.
        • Ford I.
        • Dubost-Brama A.
        • Lerebours G.
        • Tavazzi L.
        Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.
        Lancet. 2010; 376: 875-885
        • Bui A.L.
        • Grau-Sepulveda M.V.
        • Hernandez A.F.
        • Peterson E.D.
        • Yancy C.W.
        • Bhatt D.L.
        • Fonarow G.C.
        Admission heart rate and in-hospital outcomes in patients hospitalized for heart failure in sinus rhythm and in atrial fibrillation.
        Am Heart J. 2013; 165: 567-574 e6
        • Franke J.
        • Wolter J.S.
        • Meme L.
        • Keppler J.
        • Tschierschke R.
        • Katus H.A.
        • Zugck C.
        Optimization of pharmacotherapy in chronic heart failure: is heart rate adequately addressed?.
        Clin Res Cardiol. 2013; 102: 23-31
        • Elder D.H.
        • Mohan M.
        • Cochrane L.
        • Charles H.
        • Lang C.C.
        Characterizing patients with chronic heart failure in community care after hospitalization: a potential role for ivabradine.
        Cardiovasc Ther. 2015; 33: 104-108
        • Dierckx R.
        • Cleland J.G.F.
        • Parsons S.
        • Putzu P.
        • Pellicori P.
        • Dicken B.
        • Boyalla V.
        • Clark A.L.
        Prescribing patterns to optimize heart RateAnalysis of 1,000 consecutive outpatient appointments to a single heart failure clinic over a 6-month period.
        JACC Heart Fail. 2015; 3: 224-230
        • Boyle C.A.
        • Decoufle P.
        National sources of vital status information: extent of coverage and possible selectivity in reporting.
        Am J Epidemiol. 1990; 131: 160-168
        • Yancy C.W.
        • Jessup M.
        • Bozkurt B.
        • Butler J.
        • Casey D.E.
        • Drazner M.H.
        • Fonarow G.C.
        • Geraci S.A.
        • Horwich T.
        • Januzzi J.L.
        • Johnson M.R.
        • Kasper E.K.
        • Levy W.C.
        • Masoudi F.A.
        • McBride P.E.
        • McMurray J.J.V.
        • Mitchell J.E.
        • Peterson P.N.
        • Riegel B.
        • Sam F.
        • Stevenson L.W.
        • Tang W.H.W.
        • Tsai E.J.
        • Wilkoff B.L.
        2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
        Circulation. 2013; 128: e240-e319
        • Maggioni A.P.
        • Dahlstrom U.
        • Filippatos G.
        • Chioncel O.
        • Leiro M.C.
        • Drozdz J.
        • Fruhwald F.
        • Gullestad L.
        • Logeart D.
        • Metra M.
        • Parissis J.
        • Persson H.
        • Ponikowski P.
        • Rauchhaus M.
        • Voors A.
        • Nielsen O.W.
        • Zannad F.
        • Tavazzi L.
        EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot).
        Eur J Heart Fail. 2010; 12: 1076-1084
        • Persson H.
        • Erntell H.
        • Eriksson B.
        • Johansson G.
        • Swedberg K.
        • Dahlstrom U.
        Improved pharmacological therapy of chronic heart failure in primary care: a randomized Study of NT-proBNP Guided Management of Heart Failure–SIGNAL-HF (Swedish Intervention study–Guidelines and NT-proBNP AnaLysis in Heart Failure).
        Eur J Heart Fail. 2010; 12: 1300-1308
        • Lowrie R.
        • Mair F.S.
        • Greenlaw N.
        • Forsyth P.
        • McConnachie A.
        • Richardson J.
        • Khan N.
        • Morrison D.
        • Messow C.M.
        • Rae B.
        • McMurray J.J.
        The Heart failure and Optimal Outcomes from Pharmacy Study (HOOPS): rationale, design, and baseline characteristics.
        Eur J Heart Fail. 2011; 13: 917-924
        • Gheorghiade M.
        • Albert N.M.
        • Curtis A.B.
        • Thomas Heywood J.
        • McBride M.L.
        • Inge P.J.
        • Mehra M.R.
        • O'Connor C.M.
        • Reynolds D.
        • Walsh M.N.
        • Yancy C.W.
        • Fonarow G.C.
        Medication dosing in outpatients with heart failure after implementation of a practice-based performance improvement intervention: findings from IMPROVE HF.
        Congest Heart Fail. 2012; 18: 9-17
        • Cullington D.
        • Goode K.M.
        • Clark A.L.
        • Cleland J.G.
        Heart rate achieved or beta-blocker dose in patients with chronic heart failure: which is the better target?.
        Eur J Heart Fail. 2012; 14: 737-747
        • Verbrugge F.H.
        • Duchenne J.
        • Bertrand P.B.
        • Dupont M.
        • Tang W.H.
        • Mullens W.
        Uptitration of renin-angiotensin system blocker and beta-blocker therapy in patients hospitalized for heart failure with reduced versus preserved left ventricular ejection fractions.
        Am J Cardiol. 2013; 112: 1913-1920
        • Maggioni A.P.
        • Anker S.D.
        • Dahlstrom U.
        • Filippatos G.
        • Ponikowski P.
        • Zannad F.
        • Amir O.
        • Chioncel O.
        • Leiro M.C.
        • Drozdz J.
        • Erglis A.
        • Fazlibegovic E.
        • Fonseca C.
        • Fruhwald F.
        • Gatzov P.
        • Goncalvesova E.
        • Hassanein M.
        • Hradec J.
        • Kavoliuniene A.
        • Lainscak M.
        • Logeart D.
        • Merkely B.
        • Metra M.
        • Persson H.
        • Seferovic P.
        • Temizhan A.
        • Tousoulis D.
        • Tavazzi L.
        Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry.
        Eur J Heart Fail. 2013; 15: 1173-1184